- Samkwang Medical Foundation and SML Genetree jointly participated as Platinum Sponsors at LMCE 2024.
- Jo Young-sook, Director of External Relations at Samkwang Medical Foundation, received the KSLM Achievement Award.
- SML Genetree introduced the new NamuPlex™ brand.
- Both organizations aim to lead the development of the diagnostic testing field through continuous research and academic exchange, contributing to the improvement of public health.
Samkwang Medical Foundation (Chairman Hwang Tae-guk) and SML Genetree (CEO Lee Dong-soo) announced that they jointly participated as Platinum Sponsors in the LMCE 2024, held from September 25 to 27 at COEX in Seoul. During the event, they operated a joint exhibition booth and engaged in various academic activities.
During the conference, Samkwang Medical Foundation presented various diagnostic tests through its exhibition booth, including High-Resolution Chromosome Microarray Analysis (CMA), Non-hereditary Solid Tumor Gene Panel Testing, Rapid CRE Genotyping (Xpert), Helicobacter Pylori Clarithromycin Resistance Mutation Testing, and M2BPGi testing. Additionally, they promoted the Samkwang Labtree Gene-BTI Disease Prediction Gene Testing Service and their clinical trial specialist analysis institution, SML Meditree.
SML Genetree unveiled its newly rebranded NamuPlex™ brand at the event, highlighting the NamuPlex™ Mp-dR Resistance Real-time PCR Kit (RUO) for detecting Mycoplasma pneumoniae drug resistance. They also introduced the GenetreEX™ 96 Nucleic Acid Extraction System, capable of extracting 96 samples simultaneously in around 30 minutes, along with the GenetreEX™ Viral TNA Kit. These systems offer a comprehensive solution for extracting DNA and RNA needed for disease diagnosis, garnering significant interest and positive feedback from attendees.
The LMCE 2024 was held under the theme "Digital Transformation of Laboratory Medicine; Empowering Diagnostics." Over 2,500 participants and 90 companies from 32 countries has participated. The event provided a platform to share the latest trends and research achievements in in vitro diagnostic medical devices and laboratory medicine through various academic activities.
Additionally, at the award ceremony during the Korean Society for Laboratory Medicine's general meeting, Jo Young-sook, Director of External Relations at Samkwang Medical Foundation, was recognized for her continued efforts and contributions to the development of laboratory medicine. She received the Achievement Award from the Korean Association of Clinical Testing Institutions.
Hwang Tae-guk, Chairman of Samkwang Medical Foundation, expressed that it was meaningful to successfully showcase the innovative technologies and services of Samkwang Medical Foundation and SML Genetree at the LMCE 2024. He emphasized that the foundation will continue to lead the development of the diagnostic testing field through ongoing research and academic exchanges, ultimately aiming to improve customer satisfaction and contribute to public health.
Excerpted from 2024.10.02 // Medicom// news@mdon.co.kr // www.mdon.co.kr/news/article.html?no=33703
Samkwang Medical Foundation (Chairman Hwang Tae-guk) and SML Genetree (CEO Lee Dong-soo) announced that they jointly participated as Platinum Sponsors in the LMCE 2024, held from September 25 to 27 at COEX in Seoul. During the event, they operated a joint exhibition booth and engaged in various academic activities.
During the conference, Samkwang Medical Foundation presented various diagnostic tests through its exhibition booth, including High-Resolution Chromosome Microarray Analysis (CMA), Non-hereditary Solid Tumor Gene Panel Testing, Rapid CRE Genotyping (Xpert), Helicobacter Pylori Clarithromycin Resistance Mutation Testing, and M2BPGi testing. Additionally, they promoted the Samkwang Labtree Gene-BTI Disease Prediction Gene Testing Service and their clinical trial specialist analysis institution, SML Meditree.
SML Genetree unveiled its newly rebranded NamuPlex™ brand at the event, highlighting the NamuPlex™ Mp-dR Resistance Real-time PCR Kit (RUO) for detecting Mycoplasma pneumoniae drug resistance. They also introduced the GenetreEX™ 96 Nucleic Acid Extraction System, capable of extracting 96 samples simultaneously in around 30 minutes, along with the GenetreEX™ Viral TNA Kit. These systems offer a comprehensive solution for extracting DNA and RNA needed for disease diagnosis, garnering significant interest and positive feedback from attendees.
The LMCE 2024 was held under the theme "Digital Transformation of Laboratory Medicine; Empowering Diagnostics." Over 2,500 participants and 90 companies from 32 countries has participated. The event provided a platform to share the latest trends and research achievements in in vitro diagnostic medical devices and laboratory medicine through various academic activities.
Additionally, at the award ceremony during the Korean Society for Laboratory Medicine's general meeting, Jo Young-sook, Director of External Relations at Samkwang Medical Foundation, was recognized for her continued efforts and contributions to the development of laboratory medicine. She received the Achievement Award from the Korean Association of Clinical Testing Institutions.
Hwang Tae-guk, Chairman of Samkwang Medical Foundation, expressed that it was meaningful to successfully showcase the innovative technologies and services of Samkwang Medical Foundation and SML Genetree at the LMCE 2024. He emphasized that the foundation will continue to lead the development of the diagnostic testing field through ongoing research and academic exchanges, ultimately aiming to improve customer satisfaction and contribute to public health.
Excerpted from 2024.10.02 // Medicom// news@mdon.co.kr // www.mdon.co.kr/news/article.html?no=33703